These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 14645020)

  • 1. Quantitative analysis of sponsorship bias in economic studies of antidepressants.
    Baker CB; Johnsrud MT; Crismon ML; Rosenheck RA; Woods SW
    Br J Psychiatry; 2003 Dec; 183():498-506. PubMed ID: 14645020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
    Laux G
    Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of depression with and without headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Kuo KH; Wang SJ
    J Affect Disord; 2015 Jan; 170():255-65. PubMed ID: 25261631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies.
    Barbui C; Percudani M; Hotopf M
    J Clin Psychopharmacol; 2003 Apr; 23(2):145-54. PubMed ID: 12640216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant agents: from tricyclics to serotonin uptake inhibitors.
    Garattini S; Barbui C; Saraceno B
    Psychol Med; 1998 Sep; 28(5):1169-78. PubMed ID: 9794024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002791. PubMed ID: 17636706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
    Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
    Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine versus other types of pharmacotherapy for depression.
    Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
    Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
    Crown WH
    Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
    Berndt ER; Bhattacharjya A; Mishol DN; Arcelus A; Lasky T
    J Ment Health Policy Econ; 2002 Mar; 5(1):3-19. PubMed ID: 12529566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conflict of interest in industry-sponsored economic evaluations: real or imagined?
    Barbieri M; Drummond MF
    Curr Oncol Rep; 2001 Sep; 3(5):410-3. PubMed ID: 11489241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the consumption of antidepressant drugs in Lithuania in 2002-2004.
    Kadusevicius E; Mikucionyte L; Maciulaitis R; Milvidaite I; Sveikata A
    Medicina (Kaunas); 2006; 42(12):1020-9. PubMed ID: 17211111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressants for the treatment of depression in people with cancer.
    Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are SSRIs a cost-effective alternative to tricyclics?
    Hotopf M; Lewis G; Normand C
    Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.